SCHEMBL4870705

SCHEMBL4870705

COC(=O)c1cc(-c2nccs2)cc2c1OC(c1ccccc1)(c1ccccc1)O2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 1/20 0.38
PDPK1 O15530 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
SMPD3 Q9NY59 1/20 0.37
AXL P30530 2/20 0.36
HDAC2 Q92769 2/20 0.36
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
TRPM4 Q8TD43 1/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 1/20 0.35
TP53 P04637 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4870745 0.88 PDPK1 (0.41) PDPK1PTGDR2HDAC2TRPM4KAT6A
SCHEMBL4871083 0.82 ALDH1A1 (0.41) AXLKMT2AMEN1KDM4EALDH1A1
SCHEMBL4867176 0.81 NR4A2 (0.41) AXLKMT2AMEN1KDM4EALDH1A1
SCHEMBL4868951 0.78 SLC6A4 (0.46) KMT2AMEN1KDM4EALDH1A1TP53
SCHEMBL4868416 0.76 ALDH1A1 (0.41) KMT2AMEN1KDM4EALDH1A1GAA
SCHEMBL4868406 0.76 KDM4E (0.42) KMT2AMEN1KDM4EALDH1A1GAA
SCHEMBL4863014 0.74 KDM4E (0.37) KDM4EALDH1A1MAPTHPGDTSHR
SCHEMBL4867441 0.73 CNR1 (0.41) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL8285503 0.72 TRPA1 (0.47) KMT2AKDM4EALDH1A1GAAMAPT
SCHEMBL4871124 0.72 KDM4E (0.40) KMT2AMEN1KDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-A2 COMT INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-09-06 EP disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition F. HOFFMANN-LA ROCHE AG (CH) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition COMT, MAOB, TPH1 TACR3 2040/4885PDPK1 919/4885PTGDR2 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.